Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05518487 · ClinicalTrials.gov registry record · Phase 2
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
A Phase 2 study of COVID-19 and Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 6
- Study locations
NCT05518487 is a Phase 2 study of COVID-19 and Kidney Transplant that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 15 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05518487, a Phase 2 study of COVID-19 and Kidney Transplant, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 6
- Study locations
Study Summary
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80 participants will be enrolled in this study. Eligible participants will receive a dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine candidate.. The primary objective is to determine whether a booster dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine will elicit an increased SARS-CoV-2 antibody response in participants who have failed to maintain an antibody titer \>2500 U/mL (using the Roche Elecsys(R) anti-RBD assay) to 2 or more doses of mRNA based COVID-19 vaccine
Conditions Studied
Interventions
- BIOLOGICAL Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Study Locations (6)
California
- University of California San Diego Medical Center: Transplantation - San Diego
- UCSF School of Medicine: Transplantation - San Francisco
Georgia
- Emory University School of Medicine: Transplantation - Atlanta
Illinois
- University of Illinois Medical Center: Transplantation - Chicago
Maryland
- Johns Hopkins Institute for Clinical and Translational Research: Broadway Adult Outpatient Clinical Research Unit - Baltimore
Wisconsin
- University of Wisconsin School of Medicine and Public Health: Transplantation - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2024-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05518487
The ClinicalTrials.gov registry entry for NCT05518487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine is the first listed.
NCT05518487 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05518487 about?
NCT05518487 is a clinical study titled "COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study". An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80 participants will be enrol...
What is the current status of trial NCT05518487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-02-20. Estimated completion is 2024-11-06.
What conditions does trial NCT05518487 study?
This clinical trial studies the following conditions: COVID-19, Kidney Transplant.
What interventions are being tested in trial NCT05518487?
The interventions under investigation include: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05518487?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05518487 being conducted?
This trial has 6 study locations across California, Georgia, Illinois, Maryland, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.